ASSESSMENT OF SERUM ALKALINE PHOSPHATASE IN PATIENTS DIAGNOSED WITH METABOLIC SYNDROME
Main Article Content
Keywords
Metabolic syndrome (MetS), Serum alkaline phosphatise (ALP), Cardiometabolic risk, Biomarker, Insulin resistance, Inflammation
Abstract
Introduction: Metabolic syndrome (MetS) is a cluster of interrelated metabolic abnormalities, including central obesity, elevated blood pressure, hyperglycaemia, and dyslipidaemia. Together, these conditions substantially increase the risk of developing cardiovascular disease and type 2 diabetes mellitus. Serum alkaline phosphatase (ALP), an enzyme primarily derived from the liver and bones, is commonly assessed as part of routine liver function testing. However, emerging evidence indicates that elevated ALP levels may also be associated with metabolic disturbances and an increased risk of cardiovascular complications.
Methods: This study included 80 individuals aged 18–50 years. They were divided into two groups. Group 1 (40 patients) had MetS based on ATP III guidelines. Group 2 (40 healthy volunteers) were matched by age and gender. Blood samples were collected from all participants, and serum ALP levels were measured using standard laboratory methods. The difference between the two groups was analyzed using an unpaired t-test.
Results: People with metabolic syndrome had higher ALP levels (124.15 ± 61.47 U/L) compared to the healthy group (88.97 ± 24.69 U/L). This difference was statistically significant (p < 0.05).
Conclusion: Serum ALP levels were elevated in individuals with metabolic syndrome, indicating a potential association between ALP and underlying metabolic alterations as well as increased health risks. Further research is required to clarify the mechanisms responsible for the rise in ALP levels in these patients.
References
2. Lent-Schochet D, McLaughlin M, Ramakrishnan N, Jialal I. Exploratory metabolomics of metabolic syndrome: a status report. World J Diabetes. 2019;10:23.
3. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
4. Singh J, Rajput M, Rajput R, Bairwa M. Prevalence and predictors of metabolic syndrome in a North Indian rural population: a community-based study. J Glob Diabetes Clin Metab. 2016;5:2.
5. Krishnamoorthy Y, Rajaa S, Murali S, Rehman T, Sahoo J, Kar SS. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS One. 2020;15:e0240971.
6. Lind L, Sundström J, Ärnlöv J, Risérus U, Lampa E. A longitudinal study over 40 years to study the metabolic syndrome as a risk factor for cardiovascular diseases. Sci Rep. 2021;11:2978.
7. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786.
8. Khatiwada S, Sah SK, Kc R, Baral N, Lamsal M. Thyroid dysfunction in metabolic syndrome patients and its relationship with components of metabolic syndrome. Clin Diabetes Endocrinol. 2016;2:1–5.
9. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120(18):1784–92.
10. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(11):1805–10.
11. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;75(5):655–63.
12. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48(1):59–68.
13. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr. 2007;17(1):38–44.
14. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19(11):2193–203.
15. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51(5):877–84.
16. Robinson D, Sandblom G, Johansson R, et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate-specific antigen and alkaline phosphatase. J Urol. 2008;179(1):117–22.
17. Lara PN Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512–16.
18. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74(5):655–63.
19. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54(11):3140–47.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
